Trials / Terminated
TerminatedNCT05362474
Targeting Leukotrienes in Kidney Disease
Targeting Leukotrienes in Kidney Disease: A Pilot Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Montelukast | 10mg orally once a day |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-06-20
- Completion
- 2023-06-20
- First posted
- 2022-05-05
- Last updated
- 2025-05-30
- Results posted
- 2025-05-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05362474. Inclusion in this directory is not an endorsement.